奥曲肽治疗肝硬化顽固性腹水疗效的Meta分析

doi:10.3969/j.issn.1671-7171.2017.01.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】评价奥曲肽治疗肝硬化顽固性腹水的疗效和安全性。【方法】计算机检索PubMed、Embase、Cochrane Library、CBMdisc、CNKI、维普、万方等数据库公开发表的文献,检索年限均从2000年1月至2015年7月。纳入奥曲肽联合内科常规治疗(观察组)与单纯内科常规治疗(对照组)相比较治疗肝硬化顽固性腹水的随机对照试验。由两名评判员对纳入试验独立进行质量评价和资料提取,采用RevMan5.2软件进行Meta分析。【结果】经筛选共纳入10个随机对照试验,合计757例患者。Meta分析结果显示:观察组的总有效率和24 h尿量均高于对照组[OR=2.86,95%CI(1.90,4.31),P＜0.05;MD= 259.80,95%CI(249.45,270.15),P＜0.05],腹围和体质量均低于对照组[MD= -11.72,95%CI(-13.30,-10.14),P＜0.05;MD= -4.80,95%CI(-7.02,-2.58),P＜0.05]。【结论】奥曲肽可显著增加肝硬化顽固性腹水患者的24 h尿量,降低其腹围和体质量,提高其治疗的总有效率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姚玲
	毛海鹰
	陈琴
	何莲

关键词 ：奥曲肽/治疗应用, 肝硬化/并发症, 腹水/病因学, Meta分析

Abstract：【Objective】 To evaluate the efficacy and safety of octreotide in patients with refractory ascites due to cirrhosis. 【Methods】 The relevant randomized controlled trials were searched throughout PubMed, Embase, Cochrane Library, CBMdisc, CNKI, Chinese VIP database, and WanFang database. All articles were identified by a search from January 2000 to July 2015. Trials comparing the efficacy of octreotide plus routine medical therapy versus routine medical therapy in patients with refractory ascites due to cirrhosis were included. Two investigators independently assessed the methodological quality of included trials and performed the data extraction. Meta-analysis was carried out with Review Manager Software 5.2. 【Results】 Ten eligible trials including 757 patients were included and assessed. According to the results of the meta-analysis, octreotide plus routine medical therapy was remarkably more effective than routine medical therapy in terms of total effective rate [OR=2.86, 95%CI(1.90, 4.31),P<0.05], 24-hour urine volume [MD=259.80, 95%CI(249.45, 270.15),P<0.05], abdominal perimeter [MD=-11.72, 95%CI(-13.30, -10.14),P<0.05], and body weight [MD=-4.80, 95%CI(-7.02, -2.58),P<0.05]. 【Conclusions】 Octreotide can significantly increase the 24-hour urine volume, reduce the abdominal perimeters and body weight, and raise the total effective rate in patients with refractory ascites due to cirrhosis.

Key words： Octreotide/TU Liver Cirrhosis/CO Ascites/ET Meta-Analysis

收稿日期: 2015-09-06

PACS:

引用本文:

姚玲;毛海鹰;陈琴;何莲. 奥曲肽治疗肝硬化顽固性腹水疗效的Meta分析[J]. 医学临床研究, 2017, 34(1): 56-60.
YAO Ling, MAO Hai-ying, CHEN Qin, et al. Meta-Analyisis of the Efficacy of Octreotide in Patients with Refractory Ascites due to Cirrhosis. JOURNAL OF CLINICAL RESEARCH, 2017, 34(1): 56-60.

链接本文:

http://www.jcr.net.cn/CN/10.3969/j.issn.1671-7171.2017.01.019 或 http://www.jcr.net.cn/CN/Y2017/V34/I1/56

[1] Runyon BA,AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update[J].Hepatology,2009,49(6):2087-2107.
[2] 王菲,王炳元.2010年欧洲肝硬化腹水临床实践指南介绍[J].中华肝脏病杂志,2010,18(12):951-954.
[3] 王宇明.肝硬化合并低钠血症-顽固性腹水-急性肾损伤的防治新认识[J].中华肝脏病杂志,2012,20(7):481-486.
[4] 余洋.小剂量奥曲肽治疗肝硬化顽固性腹水的临床疗效观察[J].吉林医学,2012,33(18):3895.
[5] 侯金亭.小剂量奥曲肽治疗肝硬化顽固性腹水的临床疗效分析[J].中国现代药物应用,2012,6(20):70-71.
[6] 唐简,周艳,彭忠田.小剂量奥曲肽治疗肝硬化顽固性腹水的疗效观察[J].医学临床研究,2013,30(7):1437-1438.
[7] 徐静,汪茂荣,盛云峰,等.小剂量奥曲肽治疗肝硬化顽固性腹水33例临床疗效及安全性分析[J].实用肝脏病杂志,2014,17(4):418-419.
[8] 曾东.小剂量奥曲肽治疗肝硬化顽固性腹水的临床疗效分析[J].医学信息,2013,26(5):464.
[9] 王红.奥曲肽治疗肝硬化难治性腹水的临床疗效观察[J].心理医生杂志,2012,12(230):284-285.
[10] 石翠翠,邓长卿,刘涛,等.奥曲肽治疗顽固性腹水的疗效观察[J].苏州大学学报(医学版),2011,31(6):989-991.
[11] 胡景芝,张兵.奥曲肽治疗肝硬化顽固性腹水临床疗效观察[J].中国保健营养,2012,9(下):3390.
[12] 詹莉.肝硬化顽固性腹水治疗效果观察[J].今日健康,2014,13(3):58.
[13] 苗玉永.奥曲肽治疗乙肝后肝硬化失代偿期顽固性腹水疗效观察[J].中国保健营养,2014,6(中):3527-3528.
[14] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol,2010,53(3):397-417.
[15] 伏爱国,郝波,任清华,等.奥曲肽辅助治疗肝硬化食管胃底静脉曲张破裂出血疗效分析[J].中华实用诊断与治疗杂志,2009,23(1):68-69.
[16] Kalambokis G, Fotopoulos A, Economou M,et al.Octreotide in the treatment of refractory ascites of cirrhosis[J].Scand J Gastroenterol,2006,41(1):118-121.